Quick Heal Technologies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
QUICKHEAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Quick Heal Technologies reported weak Q1 FY26 (quarter ended June 30, 2025) results. Consolidated revenue fell 18.6% year-on-year to ₹57.2 crore from ₹70.3 crore in Q1 FY25. The company swung to a loss with EBITDA of ₹(9.7) crore versus a positive ₹2.6 crore last year, and EBITDA margin compressed sharply to -17.0% from 3.7%. Profit after tax (PAT) was ₹(5.5) crore compared to a profit of ₹4.0 crore in Q1 FY25, translating to a diluted EPS of ₹(1.0). The consumer business was the main drag, declining about 27.8% YoY to ₹31.7 crore, while enterprise revenue fell a milder 2.3% to ₹31.7 crore. Management cited consumer headwinds and deferred enterprise deal closures but highlighted international revenue growth of roughly 2x YoY and deferred revenue of ₹16.6 crore.
This is a clearly negative quarter – both revenue and profitability deteriorated sharply, pushing the company into operating losses. Shareholders should expect near-term pressure on the stock given the weak print, though management's commentary on pipeline build-up, new product launches and international expansion may cushion sentiment. Investors should watch for recovery in the consumer segment and stabilization of margins in the coming quarters.